Kevin P. Starr

Kevin P. Starr (board member) discloses dealings in 10 companies, chiefly Sage Therapeutics, Inc., Alnylam Pharmaceuticals, Inc. and Larimar Therapeutics, Inc. Over a trading history stretching from 10 July 2007 to 16 June 2021, the count stands at 117 filings.

In open-market terms, that means 1 purchase worth €834k on one side and 33 sales worth €115.4M on the other. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants and 12 option exercises. In 2021 alone, the filings show 1 purchase and no sales.

Most recently, on 17 June 2021, the filings show an open-market purchase worth €834k in Sage Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.